Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Fintel reports that on July 18, 2025, Jefferies upgraded their outlook for Abbott Laboratories (NYSE:ABT) from Hold to Buy.

Abbott Laboratories (NYSE:ABT) now projects organic sales growth, excluding COVID-19 testing-related sales, to grow between 7 ...

Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer’s top stocks for most of this year, this show saw the CNBC TV host take a different tone.

Abbott Laboratories stock falls after earnings even as the company reports second-quarter sales that top expectations.

The governor appeared to walk back his calls last month for lawmakers to regulate the state’s burgeoning THC industry like it ...

This was the stock's third consecutive day of gains.

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.26 EPS, expectations were $1.26. Operator: Good morning, and thank you ...

Abbott Laboratories ABT is preparing to release its quarterly earnings on Thursday, 2025-07-17. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Abbott Laboratories closed 14.67% below its 52-week high of $141.23, which the company achieved on March 4th.